Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells

This billing guidance states that the Biocept Target Selector HER2 Assay and the AR-V7 Protein Test are considered reasonable and necessary when billed in accordance with Local Coverage Determination L38566. Claims must use CPT 81479 with 1 unit of service, include the appropriate DEX Z-Code™ adjacent to the CPT code in the specified claim fields for Part A or B, and report an appropriate ICD-10-CM diagnosis code.

"Biocept Target Selector HER2 Assay is considered reasonable and necessary per this billing guidance in accordance with LCD L38566."

Sign up to see full coverage criteria, indications, and limitations.